Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.
MediWound Ltd (Nasdaq: MDWD) is a biopharmaceutical innovator developing enzymatic therapeutics for non-surgical wound care. This page provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic developments.
Access consolidated information about NexoBrid adoption, EscharEx clinical trials, and pipeline progress. Stay informed about financial results, partnership announcements, and market expansion initiatives directly impacting MediWound's position in wound care innovation.
Key updates include FDA/EMA regulatory decisions, burn treatment protocols, chronic wound therapy breakthroughs, and peer-reviewed research findings. All content is verified through primary sources to ensure accuracy for investment and clinical decision-making.
Bookmark this page for streamlined access to MediWound's latest developments. Combine our updates with SEC filings and earnings call transcripts for comprehensive analysis of this enzymatic therapeutics leader.
MediWound (Nasdaq: MDWD) announced plans to present 10 scientific abstracts at two major wound care conferences: the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2025 in Grapevine, Texas.
The presentations will showcase new data on EscharEx®, their investigational enzymatic therapy for chronic wounds. Key highlights include:
- New in vitro data demonstrating EscharEx's selective proteolytic activity
- Results showing superior debridement efficacy compared to SANTYL®
- Case studies on EscharEx's use in advanced diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs)
- Updates on the ongoing VALUE Phase III study
The VALUE Phase III study is actively enrolling VLU patients across multiple sites, building on positive results from three completed Phase II studies that demonstrated EscharEx's efficacy and safety in wound care.
MediWound (NASDAQ: MDWD) reported its Q4 and full-year 2024 financial results, achieving $20.2 million in annual revenue, up from $18.7 million in 2023. The company projects $24 million revenue for 2025.
Key developments include initiating the VALUE Phase III trial for EscharEx® in venous leg ulcers, expanding strategic collaborations with industry leaders including Kerecis, and securing €16.5 million in European Innovation Council funding. NexoBrid® showed strong momentum with U.S. hospital orders increasing 42% in Q4.
Financial highlights: Q4 revenue reached $5.8 million with a 15.5% gross margin. Full-year net loss was $30.2 million ($3.03 per share), significantly higher than 2023's $6.7 million loss, primarily due to warrant revaluation expenses. The company ended 2024 with $43.6 million in cash and secured $25 million through a strategic PIPE investment led by Mölnlycke Health Care.
MediWound (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, has scheduled its Fourth Quarter and Full Year 2024 financial results release for Wednesday, March 19, 2025. The company will host a conference call and live webcast at 8:30 a.m. Eastern Time on the same day to discuss the financial results and provide corporate updates.
MediWound (Nasdaq: MDWD) announced the publication of its Phase III Children Innovative Debridement Study (CIDS) in Burns, the peer-reviewed Journal of the International Society for Burn Injuries. The study evaluated NexoBrid® compared to standard of care in pediatric patients with deep thermal burns.
The publication, titled "Open-Label RCT of the Efficacy and Safety of NexoBrid Compared to SOC in Children with Burns," presents findings that supported NexoBrid's label expansion for pediatric patients in the E.U. (2023) and U.S. (2024). The results confirm NexoBrid's superiority as a rapid, effective, and non-surgical alternative for eschar removal in pediatric burn patients.
Professor Jose Ramón Martínez-Méndez noted that pediatric burn patients account for approximately 30% of all burn cases and present unique challenges. NexoBrid provides a non-surgical solution that effectively removes eschar while preserving healthy tissue, addressing the need to protect viable dermis and improve outcomes.
MediWound (Nasdaq: MDWD), a specialist in enzymatic therapeutics for tissue repair, has announced its participation in the 45th Annual TD Cowen Health Care Conference in Boston. CEO Ofer Gonen will deliver a corporate overview on March 5, 2025, at 11:50 AM ET.
The presentation will be accessible through a live webcast, with registration available online. A replay will be made available on MediWound's website in the Events & Presentations section of the Investors area. The management team will also conduct one-on-one meetings with investors during the conference, which can be arranged through TD Cowen representatives.
MediWound (MDWD) has launched VALUE, a global Phase III pivotal trial for EscharEx® in treating venous leg ulcers (VLUs). The trial will evaluate the drug's efficacy and safety across 40 sites in the U.S. and Europe, enrolling 216 patients in a randomized, double-blind, placebo-controlled study.
The study will assess EscharEx's ability to achieve complete debridement and wound closure. Patients will receive up to eight daily applications over two weeks, followed by ten weeks of wound management. An interim analysis is expected in mid-2026 after 65% of patients complete treatment.
MediWound has established collaborations with Solventum, Mölnlycke, and MIMEDX to support the trial. The company also plans to initiate a head-to-head Phase II study comparing EscharEx to collagenase in 2025, and a Phase II/III trial for diabetic foot ulcers in 2026.
MediWound (Nasdaq: MDWD), a pioneer in enzymatic therapeutics for tissue repair, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. CEO Ofer Gonen will engage in a fireside chat on February 12, 2025, at 8:00 AM ET, moderated by Francois Brisebois, Managing Director and Senior Biotechnology Research Analyst at Oppenheimer.
The virtual event will be accessible through registration, and a webcast link will be available on MediWound's website under the Events & Presentations section. The management team will also conduct one-on-one meetings with investors during the conference, which can be arranged through Oppenheimer representatives.
MediWound (MDWD) announced a virtual Key Opinion Leader (KOL) event scheduled for January 8, 2025, at 10:00 AM ET. The event will focus on EscharEx®, their biologic drug in late-stage clinical development for chronic wound debridement, specifically discussing the upcoming Phase III VALUE study in venous leg ulcers (VLUs) and its commercial potential.
The event will feature three distinguished clinical experts from prestigious institutions who will discuss compelling Phase II study results, the Phase III VALUE study, unmet needs in VLUs and diabetic foot ulcers (DFUs) treatment, and EscharEx's competitive advantages. A Q&A session with the experts and MediWound's leadership team will follow the presentations.
MediWound reported Q3 2024 financial results with revenue of $4.4 million, down from $4.8 million in Q3 2023. The company achieved FDA approval for NexoBrid pediatric use and plans to submit an IND for EscharEx Phase 3 study by year-end. Notable developments include a $25 million PIPE financing and €16.25 million EIC funding. The company's new manufacturing facility is under commissioning, expected to increase capacity sixfold by end of 2025. Updated 2024 revenue guidance is $20 million, reduced from $24 million. Q3 net loss widened to $10.3 million compared to $2.2 million in Q3 2023, primarily due to warrant revaluation expenses.
MediWound announced it will release its third quarter 2024 financial results on November 26, 2024. The results will cover the period ending September 30, 2024. Following the release, the company's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide corporate updates. The call can be accessed using the following numbers: Toll-Free: 1-833-630-1956, Israel: 1-80-921-2373, International: 1-412-317-1837. A replay of the webcast will be available on the Investors section of the MediWound website.
